Atacama was founded by a team of experienced life science professionals to advance a treatment for hyperhidrosis and establishing proof-of-concept for TC-5214 in this indication. Hyperhidrosis represents a disease with a significant unmet medical and quality of life need where only a few treatments have been approved by regulatory authorities.
Primary hyperhidrosis (PH) caused by overactive sweat glands. Sweat gland activity is controlled nervous system mediated through a molecule called acetylcholineMore Info
Atacama has assembled a top team of dermatology veterans and biotech executives and is seeking potential partners for its hyperhidrosis and its early stage programs.More Info
Atacama expects to rapidly advance its program from proof of concept to a dose ranging study and anticipates initiating registration trials within two years. The Atacama team seeks to develop a portfolio of dermatology focused products for worldwide markets.More Info